Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#51 / 200 Total
BYSI - BeyondSpring Inc - Stock Price Chart
CompanyBeyondSpring Inc
Market Cap104.60MEPS (ttm)-0.54
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y25.94%
P/S59.77EPS next 5Y-
P/B-EPS Q/Q52.99%
Dividend-Sales Q/Q87.78%
Insider Own26.38%Inst Own2.38%
Insider Trans0.00%Inst Trans-20.48%
Short Float8.18%Earnings-
Analyst Recom2.00Target Price1.25
Avg Volume214.43K52W Range0.65 - 4.00
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.
RVPH - Reviva Pharmaceuticals Holdings Inc. - Stock Price Chart
CompanyReviva Pharmaceuticals Holdings Inc.
Market Cap38.53MEPS (ttm)-1.59
P/E-EPS this Y30.91%
Forward P/E-EPS next Y12.81%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q17.76%
Dividend-Sales Q/Q-
Insider Own17.71%Inst Own20.03%
Insider Trans0.00%Inst Trans-42.95%
Short Float7.76%EarningsMay 14/b
Analyst Recom1.00Target Price15.00
Avg Volume306.86K52W Range1.21 - 8.00
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.
VERU - Veru Inc - Stock Price Chart
CompanyVeru Inc
Market Cap162.48MEPS (ttm)-0.34
P/E-EPS this Y75.82%
Forward P/E-EPS next Y-13.53%
PEG-EPS past 5Y-19.79%
P/S12.05EPS next 5Y-
P/B3.59EPS Q/Q85.73%
Dividend-Sales Q/Q-37.21%
Insider Own14.00%Inst Own37.60%
Insider Trans-1.09%Inst Trans-6.50%
Short Float10.06%EarningsMay 08/b
Analyst Recom1.60Target Price3.44
Avg Volume2.40M52W Range0.36 - 1.92
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARNETTE K GARYChief Scientific OfficerMay 24 '24Buy1.345,0006,6965,000May 24 06:57 PM
FISCH HARRYChief Corporate OfficerMay 24 '24Buy1.254,0005,000774,736May 28 05:04 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 24 '24Sale1.2363,37978,1026,942,709May 24 06:51 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 23 '24Sale1.353004057,006,088May 24 06:51 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 22 '24Sale1.396,5049,0187,006,388May 24 06:51 PM
CYTO - Altamira Therapeutics Ltd - Stock Price Chart
CompanyAltamira Therapeutics Ltd
Market Cap3.61MEPS (ttm)-
P/E-EPS this Y73.72%
Forward P/E-EPS next Y25.88%
PEG-EPS past 5Y50.52%
P/S-EPS next 5Y-
P/B-EPS Q/Q87.98%
Dividend-Sales Q/Q-
Insider Own0.89%Inst Own0.07%
Insider Trans0.00%Inst Trans19.68%
Short Float4.56%EarningsApr 10/b
Analyst Recom1.00Target Price287.34
Avg Volume1.98M52W Range1.35 - 18.00
Today 10:31AM Altamira Therapeutics Provides Business Update (GlobeNewswire) -9.55%
May-24-24 08:45AM Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 (GlobeNewswire)
May-23-24 08:47AM Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal (GlobeNewswire) +19.58%
May-01-24 08:47AM Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation (GlobeNewswire)
Apr-24-24 08:47AM Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal (GlobeNewswire) -8.86%
Apr-17-24 08:00AM Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024 (GlobeNewswire) -9.20%
Apr-15-24 08:00AM Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO) (GlobeNewswire) -9.29%
Apr-12-24 08:20AM Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-10-24 08:00AM Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results (GlobeNewswire) +7.53%
Apr-04-24 08:45AM Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 (GlobeNewswire) +7.73%
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
SST - System1 Inc - Stock Price Chart
CompanySystem1 Inc
IndustrySpecialty Business Services
Market Cap91.64MEPS (ttm)-2.22
P/E-EPS this Y45.90%
Forward P/E-EPS next Y-6.82%
PEG-EPS past 5Y-
P/S0.22EPS next 5Y-
P/B0.69EPS Q/Q57.65%
Dividend-Sales Q/Q-49.41%
Insider Own68.65%Inst Own12.19%
Insider Trans1.92%Inst Trans3.43%
Short Float7.02%EarningsMay 09/a
Analyst Recom1.00Target Price5.00
Avg Volume500.75K52W Range1.04 - 4.86
System1, Inc. engages in the development of a proprietary end-to-end responsive acquisition marketing platform. It also provides antivirus and consumer privacy software solutions, offering a single packaged solution that provides protection and reporting to the end user. The company was founded by Michael Blend in 2013 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blend Stanley10% OwnerMar 19 '24Buy1.422453486,625,215Mar 19 08:29 PM
Blend Stanley10% OwnerMar 15 '24Buy1.4211,36816,1436,624,970Mar 19 08:29 PM
Blend Stanley10% OwnerDec 15 '23Buy1.42880,0001,249,6006,612,956Dec 18 07:32 PM
Cannae Holdings, Inc.10% OwnerSep 06 '23Sale1.85110,000203,50027,012,794Sep 07 05:13 PM
OFLX - Omega Flex Inc - Stock Price Chart
CompanyOmega Flex Inc
IndustrySpecialty Industrial Machinery
Market Cap592.89MEPS (ttm)1.91
P/E30.83EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y0.61%
P/S5.56EPS next 5Y-
P/B7.46EPS Q/Q-26.51%
Dividend2.25%Sales Q/Q-15.91%
Insider Own65.17%Inst Own35.97%
Insider Trans0.00%Inst Trans1.41%
Short Float6.99%EarningsMay 01/a
Analyst Recom-Target Price-
Avg Volume8.08K52W Range63.43 - 114.50
Omega Flex, Inc. engages in the manufacture and sale of flexible metal hose and accessories. It offers products to numerous industries, such as steel production, fuel-handling, semiconductor, medical, pharmaceutical, petrochemical, residential and commercial construction, and power generation. Its products include TracPipe CounterStrike, DoubleTrac, Def-Trac, industrial, and Meditrac. The company was founded in 1975 and is headquartered in Exton, PA.
LVTX - LAVA Therapeutics NV - Stock Price Chart
CompanyLAVA Therapeutics NV
Market Cap62.83MEPS (ttm)-1.08
P/E-EPS this Y22.29%
Forward P/E-EPS next Y-49.45%
PEG-EPS past 5Y86.55%
P/S5.01EPS next 5Y-
P/B1.23EPS Q/Q96.12%
Dividend-Sales Q/Q471.24%
Insider Own46.29%Inst Own14.30%
Insider Trans0.00%Inst Trans-2.67%
Short Float0.84%EarningsMay 21/b
Analyst Recom1.00Target Price6.00
Avg Volume1.06M52W Range1.13 - 6.47
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
SCNI - Scinai Immunotherapeutics Ltd ADR - Stock Price Chart
CompanyScinai Immunotherapeutics Ltd ADR
Market Cap1.73MEPS (ttm)-20.17
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y46.35%
P/S-EPS next 5Y-
P/B-EPS Q/Q-185.60%
Dividend-Sales Q/Q-
Insider Own2.25%Inst Own8.83%
Insider Trans0.00%Inst Trans-
Short Float0.13%EarningsMay 15/a
Analyst Recom1.00Target Price700.00
Avg Volume4.88K52W Range3.19 - 22.70
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
NXL - Nexalin Technology Inc - Stock Price Chart
TickerNXL [NASD]
CompanyNexalin Technology Inc
IndustryMedical Devices
Market Cap6.81MEPS (ttm)-0.67
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y2.43%
P/S42.55EPS next 5Y-
P/B2.92EPS Q/Q-36.32%
Dividend-Sales Q/Q157.43%
Insider Own20.63%Inst Own0.85%
Insider Trans0.00%Inst Trans-
Short Float1.24%Earnings-
Analyst Recom-Target Price-
Avg Volume813.56K52W Range0.25 - 3.40
Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices helps people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.
PRLD - Prelude Therapeutics Inc - Stock Price Chart
CompanyPrelude Therapeutics Inc
Market Cap203.79MEPS (ttm)-2.01
P/E-EPS this Y14.98%
Forward P/E-EPS next Y17.32%
PEG-EPS past 5Y-43.14%
P/S-EPS next 5Y30.10%
P/B0.97EPS Q/Q28.52%
Dividend-Sales Q/Q-
Insider Own52.76%Inst Own30.23%
Insider Trans0.00%Inst Trans-2.03%
Short Float2.35%EarningsMay 07/b
Analyst Recom3.00Target Price4.75
Avg Volume43.91K52W Range1.66 - 6.03
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.